Theodore R. Schroeder - Sep 30, 2022 Form 4 Insider Report for Nabriva Therapeutics plc (NBRV)

Role
Chief Executive Officer, Director
Signature
/s/ Dan Dolan, by power of attorney
Stock symbol
NBRV
Transactions as of
Sep 30, 2022
Transactions value $
-$10
Form type
4
Date filed
10/4/2022, 09:31 PM
Previous filing
Sep 7, 2022
Next filing
Oct 11, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NBRV Ordinary Shares Tax liability -$10 -5 -0.04% $2.08 12.5K Sep 30, 2022 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These ordinary shares were withheld by the Issuer in order to satisfy tax withholding obligations upon the vesting of certain restricted share units.
F2 The number of ordinary shares reported on this Form 4 reflects a 1-for-25 reverse stock split effected on September 15, 2022.